StockNews.com upgraded shares of iBio (NYSE:IBIO – Free Report) to a sell rating in a research note released on Tuesday morning.
iBio Stock Down 7.0 %
Shares of IBIO opened at $4.52 on Tuesday. The business’s 50-day moving average price is $3.85 and its 200-day moving average price is $2.92. iBio has a twelve month low of $1.05 and a twelve month high of $6.89. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.05.
Insider Activity
In other iBio news, Director David Arkowitz acquired 18,382 shares of the business’s stock in a transaction dated Friday, January 10th. The stock was bought at an average price of $2.72 per share, with a total value of $49,999.04. Following the completion of the acquisition, the director now owns 18,382 shares of the company’s stock, valued at $49,999.04. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Company insiders own 0.58% of the company’s stock.
Institutional Inflows and Outflows
About iBio
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Recommended Stories
- Five stocks we like better than iBio
- How to Calculate Inflation Rate
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- 3 REITs to Buy and Hold for the Long Term
- 3 Must-Own Stocks to Build Wealth This Decade
- Where Do I Find 52-Week Highs and Lows?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.